PDCD1 and neoplasm: Previous studies tried to approach this issue from the perspective of tumor microenvironment (TME) and found that non-T-cell-inflamed tumor microenvironment was closely associate with poor therapeutic response to immunotherapy, particularly with anti-PD-1 antibodies [14, 15].